212 related articles for article (PubMed ID: 23915419)
1. Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.
Choi JH; Schafer SC; Zhang L; Juelich T; Freiberg AN; Croyle MA
Mol Pharm; 2013 Sep; 10(9):3342-55. PubMed ID: 23915419
[TBL] [Abstract][Full Text] [Related]
2. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice.
Croyle MA; Patel A; Tran KN; Gray M; Zhang Y; Strong JE; Feldmann H; Kobinger GP
PLoS One; 2008; 3(10):e3548. PubMed ID: 18958172
[TBL] [Abstract][Full Text] [Related]
3. A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.
Choi JH; Schafer SC; Zhang L; Kobinger GP; Juelich T; Freiberg AN; Croyle MA
Mol Pharm; 2012 Jan; 9(1):156-67. PubMed ID: 22149096
[TBL] [Abstract][Full Text] [Related]
4. Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine.
Choi JH; Schafer SC; Freiberg AN; Croyle MA
Mol Pharm; 2015 Aug; 12(8):2697-711. PubMed ID: 25549696
[TBL] [Abstract][Full Text] [Related]
5. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs.
Richardson JS; Abou MC; Tran KN; Kumar A; Sahai BM; Kobinger GP
J Infect Dis; 2011 Nov; 204 Suppl 3():S1032-42. PubMed ID: 21987739
[TBL] [Abstract][Full Text] [Related]
6. An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques.
Feng Y; Li C; Hu P; Wang Q; Zheng X; Zhao Y; Shi Y; Yang S; Yi C; Feng Y; Wu C; Qu L; Xu W; Li Y; Sun C; Gao FG; Xia X; Feng L; Chen L
Emerg Microbes Infect; 2018 Jun; 7(1):101. PubMed ID: 29872043
[TBL] [Abstract][Full Text] [Related]
7. Generation of an adenoviral vaccine vector based on simian adenovirus 21.
Roy S; Zhi Y; Kobinger GP; Figueredo J; Calcedo R; Miller JR; Feldmann H; Wilson JM
J Gen Virol; 2006 Sep; 87(Pt 9):2477-2485. PubMed ID: 16894185
[TBL] [Abstract][Full Text] [Related]
8. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates.
Richardson JS; Pillet S; Bello AJ; Kobinger GP
J Virol; 2013 Apr; 87(7):3668-77. PubMed ID: 23302894
[TBL] [Abstract][Full Text] [Related]
9. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.
Kobinger GP; Feldmann H; Zhi Y; Schumer G; Gao G; Feldmann F; Jones S; Wilson JM
Virology; 2006 Mar; 346(2):394-401. PubMed ID: 16356525
[TBL] [Abstract][Full Text] [Related]
10. A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection.
Choi JH; Jonsson-Schmunk K; Qiu X; Shedlock DJ; Strong J; Xu JX; Michie KL; Audet J; Fernando L; Myers MJ; Weiner D; Bajrovic I; Tran LQ; Wong G; Bello A; Kobinger GP; Schafer SC; Croyle MA
Mol Pharm; 2015 Aug; 12(8):2712-31. PubMed ID: 25363619
[TBL] [Abstract][Full Text] [Related]
11. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
[TBL] [Abstract][Full Text] [Related]
12. Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.
Hrycak CP; Windmann S; Bayer W
J Virol; 2019 Nov; 93(21):. PubMed ID: 31375593
[TBL] [Abstract][Full Text] [Related]
13. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine.
Richardson JS; Yao MK; Tran KN; Croyle MA; Strong JE; Feldmann H; Kobinger GP
PLoS One; 2009; 4(4):e5308. PubMed ID: 19390586
[TBL] [Abstract][Full Text] [Related]
14. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
[TBL] [Abstract][Full Text] [Related]
16. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus.
Tsuda Y; Caposio P; Parkins CJ; Botto S; Messaoudi I; Cicin-Sain L; Feldmann H; Jarvis MA
PLoS Negl Trop Dis; 2011 Aug; 5(8):e1275. PubMed ID: 21858240
[TBL] [Abstract][Full Text] [Related]
17. Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.
Aviles J; Bello A; Wong G; Fausther-Bovendo H; Qiu X; Kobinger G
J Infect Dis; 2015 Oct; 212 Suppl 2():S389-97. PubMed ID: 26038398
[TBL] [Abstract][Full Text] [Related]
18. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates.
Sullivan NJ; Hensley L; Asiedu C; Geisbert TW; Stanley D; Johnson J; Honko A; Olinger G; Bailey M; Geisbert JB; Reimann KA; Bao S; Rao S; Roederer M; Jahrling PB; Koup RA; Nabel GJ
Nat Med; 2011 Aug; 17(9):1128-31. PubMed ID: 21857654
[TBL] [Abstract][Full Text] [Related]
19. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia.
Dolzhikova IV; Zubkova OV; Tukhvatulin AI; Dzharullaeva AS; Tukhvatulina NM; Shcheblyakov DV; Shmarov MM; Tokarskaya EA; Simakova YV; Egorova DA; Scherbinin DN; Tutykhina IL; Lysenko AA; Kostarnoy AV; Gancheva PG; Ozharovskaya TA; Belugin BV; Kolobukhina LV; Pantyukhov VB; Syromyatnikova SI; Shatokhina IV; Sizikova TV; Rumyantseva IG; Andrus AF; Boyarskaya NV; Voytyuk AN; Babira VF; Volchikhina SV; Kutaev DA; Bel'skih AN; Zhdanov KV; Zakharenko SM; Borisevich SV; Logunov DY; Naroditsky BS; Gintsburg AL
Hum Vaccin Immunother; 2017 Mar; 13(3):613-620. PubMed ID: 28152326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
